Beijing’s first CAR-T cell therapy approved for relapsed or refractory large B-cell lymphoma

Cointime update: Beijing Yimiao Shenzhou Biopharmaceutical Co. has received a drug registration certificate from China’s National Medical Products Administration for its self-developed CAR-T cell therapy, Boji’olunsai injection, for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. It is the first CAR-T cell therapy approved in Beijing.